This company is no longer active
Otonomy (OTIC) Stock Overview
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OTIC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Otonomy, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0085 |
| 52 Week High | US$2.54 |
| 52 Week Low | US$0.0075 |
| Beta | 1.53 |
| 1 Month Change | -91.98% |
| 3 Month Change | -91.58% |
| 1 Year Change | -99.62% |
| 3 Year Change | -99.60% |
| 5 Year Change | -99.78% |
| Change since IPO | -99.95% |
Recent News & Updates
Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails
The shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.Otonomy GAAP EPS of -$0.19 beats by $0.01
Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.Recent updates
Shareholder Returns
| OTIC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -92.6% | 0.1% | 1.6% |
| 1Y | -99.6% | 40.5% | 28.2% |
Return vs Industry: OTIC underperformed the US Pharmaceuticals industry which returned -2.3% over the past year.
Return vs Market: OTIC underperformed the US Market which returned -8.9% over the past year.
Price Volatility
| OTIC volatility | |
|---|---|
| OTIC Average Weekly Movement | 27.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OTIC's share price has been volatile over the past 3 months.
Volatility Over Time: OTIC's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 51 | n/a | www.otonomy.com |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss.
Otonomy, Inc. Fundamentals Summary
| OTIC fundamental statistics | |
|---|---|
| Market cap | US$582.48k |
| Earnings (TTM) | -US$52.26m |
| Revenue (TTM) | n/a |
Is OTIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTIC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.26m |
| Earnings | -US$52.26m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 75.4% |
How did OTIC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/13 18:09 |
| End of Day Share Price | 2023/04/11 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Otonomy, Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Gal | Bernstein |
| Sumant Satchidanand Kulkarni | BofA Global Research |
| Charles Duncan | Cantor Fitzgerald & Co. |